SCHEDULE: SR One Capital Reduces KALA BIO Stake to 5.5%

SR One Capital Management and its affiliates reported the sale of 598,940 shares of KALA BIO, Inc. common stock, reducing their beneficial ownership to 5.5%.

Summary

• SR One Capital Fund II Aggregator, LP, SR One Capital Partners II, LP, SR One Capital Management, LLC, and Simeon George, M.D. (collectively, "Reporting Persons") filed an Amendment No. 1 to their Schedule 13D for KALA BIO, Inc.
• The Reporting Persons beneficially own 411,000 shares of KALA BIO, Inc. Common Stock, representing 5.5% of the class.
• This beneficial ownership includes 4,110 shares of Series H Preferred Stock convertible into 411,000 common shares.
• The percentage is calculated based on 7,432,040 total shares, comprising 7,021,040 shares outstanding as of August 7, 2025, plus the 411,000 convertible shares.
• On September 29, 2025, SR One Capital Fund II Aggregator, LP completed open market sales of 598,940 shares of Common Stock.
• The Reporting Persons state they may dispose of additional shares depending on market conditions and other factors.
• They currently have no present plans for extraordinary corporate transactions, changes in management or board, material changes in capitalization or dividend policy, or other significant corporate structure alterations.

Sentiment

Score: 3

Explanation: The filing indicates a significant institutional investor has reduced its stake and may continue to sell, which is generally a negative signal for the company's stock performance and investor confidence.

Negatives

• A significant institutional investor, SR One Capital Fund II Aggregator, LP, sold 598,940 shares of Common Stock.
• The Reporting Persons explicitly stated they may dispose of additional shares in the future, indicating a potential continued reduction in their stake.

Risks

• Potential for further disposition of shares by SR One Capital, which could exert downward pressure on the stock price.
• The sale by a significant institutional investor may signal a lack of confidence or a shift in investment strategy regarding KALA BIO, Inc.

Future Outlook

The Reporting Persons may dispose of additional shares of KALA BIO, Inc. Common Stock in the future, depending on market conditions and other factors. They currently have no plans for other significant corporate actions involving the Issuer.

Industry Context

The reduction of a significant stake by an institutional investor like SR One Capital Management in a biotechnology company like KALA BIO, Inc. can be interpreted by the market as a signal of reduced confidence or a strategic portfolio reallocation. This could potentially lead to negative investor sentiment, especially if KALA BIO is in a critical development phase or facing competitive pressures within the biotech sector.

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding or been a party to a civil proceeding ending in a judgment, decree, or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws during the past five years.

Stakeholder Impact

• Shareholders: Potential negative impact due to increased selling pressure and a possible signal of reduced investor confidence from a significant institutional holder.
• Company Management: May face questions regarding investor sentiment and strategic direction if a major investor is reducing its stake.

Next Steps

• Reporting Persons may dispose of additional shares of the Issuer's Common Stock.

Key Dates

Recommendation

The filing reveals a significant institutional investor, SR One Capital, has substantially reduced its stake in KALA BIO, Inc. by selling 598,940 shares and explicitly stated the possibility of further dispositions. This action by a sophisticated investor often signals a lack of conviction or a strategic exit, which can exert downward pressure on the stock price and erode broader market confidence. For a seasoned investor, this would typically be a signal to consider reducing or exiting a position, especially given the potential for continued selling pressure.

Keywords

KALA BIO, SR One Capital, Schedule 13D, beneficial ownership, stock sale, institutional investor, biotechnology, equity stake, SEC filing